Lifecare ASA

Regulatory Filings • Jun 18, 2024

LIFE – LONGEVITY TRIALS IN DOGS STARTS TODAY

Bergen, Norway, 18 June 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company will starts the longevity trials in dogs today.

Reference is made to stock exchange notification June 10th and June 13th, 2024. The company have improved the read-out distance from sensor to the read-out device and the internal in-vitro quality test has been successfully conducted.

The longevity study on dogs will be performed at the Norwegian University of Life Sciences (NMBU), located in Ås, close to Oslo. Managing Director, Jo Amundstad of the subsidiary Lifecare Veterinary, will be responsible for carrying out the study in collaboration with NMBU.

– We have carried out the necessary preparations and procedures of the longevity study. The team consists of some of the leading experts in internal medicine at NMBU and their important contribution towards the study we are starting now is highly valued. Recruitment of patients has worked out as planned and the first dog is ready for implementation of the wireless sensor today, says Jo Amunstad.

Last week Lifecare Laboratory in Mainz conducted the in-vitro quality test of the wireless communication between the sensor and a read-out device. In their report they have concluded that the read-out signals from the sensor in the in-vitro testing environment meets necessary requirements from a product development perspective. Hence the company are ready to start the longevity study in dogs in today.

• The results and learnings from the longevity study and the ongoing progress towards automated production are important steps towards product readiness in the veterinary market, says CEO Joacim Holter at Lifecare.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

PRESS RELEASE 18 June 2024 08:00:00 CEST

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42